Novo Nordisk A/S (NVO) Holdings Trimmed by Founders Financial Securities LLC

Founders Financial Securities LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 49.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 11,033 shares of the company’s stock after selling 10,734 shares during the period. Founders Financial Securities LLC’s holdings in Novo Nordisk A/S were worth $531,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BB&T Corp increased its position in shares of Novo Nordisk A/S by 14.5% during the 3rd quarter. BB&T Corp now owns 128,300 shares of the company’s stock valued at $6,177,000 after purchasing an additional 16,202 shares during the last quarter. Willingdon Wealth Management increased its position in shares of Novo Nordisk A/S by 3.0% during the 2nd quarter. Willingdon Wealth Management now owns 45,316 shares of the company’s stock valued at $1,944,000 after purchasing an additional 1,325 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $1,025,000. Kidder Stephen W purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $202,000. Finally, Pinnacle Associates Ltd. increased its position in shares of Novo Nordisk A/S by 4.9% during the 2nd quarter. Pinnacle Associates Ltd. now owns 85,787 shares of the company’s stock valued at $3,679,000 after purchasing an additional 3,971 shares during the last quarter. Institutional investors and hedge funds own 6.18% of the company’s stock.

NVO has been the subject of several research reports. Bank of America raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Tuesday, October 10th. BidaskClub raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. BNP Paribas lowered shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a report on Friday, December 1st. Three analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $55.00.

In related news, insider Eric S. Sprott purchased 50,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average cost of $8.34 per share, for a total transaction of $417,000.00.

Novo Nordisk A/S (NVO) traded down $0.34 during midday trading on Wednesday, hitting $50.70. The stock had a trading volume of 1,923,400 shares, compared to its average volume of 2,098,203. The company has a market cap of $130,152.00, a P/E ratio of 22.29, a P/E/G ratio of 3.05 and a beta of 0.63. Novo Nordisk A/S has a 52-week low of $32.83 and a 52-week high of $52.32.

COPYRIGHT VIOLATION NOTICE: “Novo Nordisk A/S (NVO) Holdings Trimmed by Founders Financial Securities LLC” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/12/06/founders-financial-securities-llc-has-531000-holdings-in-novo-nordisk-as-nvo.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply